FDA finalizes Booz Allen for Spot on $300M Award to optimize DRM

U.S Food and Drug Administration ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products.

FDA’s Center for Drug Evaluation and Research (CDER) awarded Booz Allen Hamilton, one of two spots on a competitive, $300 million Blanket Purchase Agreement (BPA) over seven years to support its implementation of a transformational Informatics Platform that will enable the Agency to bring life-saving drugs to market with greater speed and efficiency.

Roman Salasznyk, Principal at Booz Allen said “Backed by our team of experienced data scientists and technologists, we will work with CDER to provide its reviewer community an integrated Platform that will enable the rapid processing, validation, management, and analysis of data across the medical product lifecycle. Holistic drug review management is the future, and we look forward to helping the FDA continue its exceptional mission performance on behalf of the American public.”